Trident Lifeline schedules AGM for September 26, FY26 results out
- Consolidated revenue rose 48% YoY to ₹129.0 crore in FY26
- Profit after tax increased 84% to ₹19.3 crore with margin expansion
- AGM agenda includes waiver of excess remuneration paid to executive director
- Shareholders to approve related party transaction caps up to ₹100 crore
*this image is generated using AI for illustrative purposes only.
Trident Lifeline has scheduled its 13th Annual General Meeting for September 26, 2026. The meeting will convene via video conferencing to transact ordinary and special business items.
The primary agenda includes the adoption of the audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026. During FY26, consolidated revenue from operations grew 48% to ₹129.0 crore, while profit after tax rose 84% to ₹19.3 crore. The consolidated EBITDA margin expanded by 470 basis points to 21.8%.
Corporate Governance and Remuneration
Shareholders will vote on the re-appointment of Hardik Jigishkumar Desai as a director, who retires by rotation. The Board also seeks approval for managerial remuneration that may exceed statutory limits under Section 197 of the Companies Act, 2013.
Additionally, the meeting will consider a special resolution to waive the recovery of excess remuneration paid to Executive Director Ashish Anandsingh Bafna. The Board noted that ₹6.37 lakh paid to him during FY26 exceeded the maximum permissible limit prescribed under the Act. The waiver is subject to shareholder approval via special resolution.
Related Party Transactions
The AGM will approve related party transactions for the financial year 2026-27. The Board seeks prior approval for transactions with subsidiaries and entities in which directors have an interest. Key related parties include Trident Mediquip Limited, TLL Parenterals Limited, and Talon Healthcare LLP.
The maximum aggregate value for transactions with Trident Mediquip Limited and TLL Parenterals Limited is set at ₹100.00 crore each annually. Transactions with other entities such as TNS Pharma Private Limited and TLL Wellness Limited are capped at ₹50.00 crore per annum. All transactions are intended to be conducted at arm's length.
Meeting Logistics
The cut-off date for determining voting rights is September 19, 2026. Remote e-voting will be available from September 23, 2026, to September 25, 2026. The company has appointed CS Mehul Amareliya as the scrutinizer for the e-voting process.
Historical Stock Returns for Trident Lifeline
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +10.16% | +9.02% | +13.77% | +12.09% | 0.0% | 0.0% |
How will the significant expansion in EBITDA margins to 21.8% influence Trident Lifeline's valuation multiples compared to industry peers?
What are the strategic implications of approving related party transactions capped at ₹100 crore for subsidiaries like Trident Mediquip and TLL Parenterals?
Could the waiver of excess remuneration for Executive Director Ashish Bafna signal broader governance risks or precedent-setting issues for future executive compensation?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
